Gastric cancer: Translating novels concepts into clinical practice - ScienceDirect
Targeted and novel therapy in advanced gastric cancer | Experimental Hematology & Oncology | Full Text
LONSURF® (trifluridine and tipiracil) tablets Efficacy | Previously Treated Metastatic GEJ and Gastric Cancer Treatment
Gastric Cancer Foundation FDA Grants Priority Review to TAS-102 for Gastric/GEJ Cancer | Gastric Cancer Foundation
Ramucirumab beyond progression plus TAS‐102 in patients with advanced or metastatic esophagogastric adenocarcinoma, after treatment failure on a ramucirumab‐based therapy - Goetze - 2023 - International Journal of Cancer - Wiley Online Library
Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Oncology
Efficacy and safety of trifluridine/tipiracil plus ramucirumab in comparison with trifluridine/tipiracil monotherapy for patients with advanced gastric cancer–single institutional experience | Gastric Cancer
Cancers | Free Full-Text | Recent Developments of Systemic Chemotherapy for Gastric Cancer
New developments and standard of care in the management of advanced gastric cancer - ScienceDirect
Cancers | Free Full-Text | Recent Trends and Advancements in the Diagnosis and Management of Gastric Cancer
Result of the PII trial of TAS-102 in third/fourth line colorectal... | Download Scientific Diagram
Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Oncology
TAGS: A Phase 3, Randomised, Double-blind Study of Trifluridine/Tipiracil ( TAS-102) Versus Placebo in Patients With Refractory Metastatic Gastric Cancer. - ppt download
Later Lines of Therapy in Metastatic Gastric Cancer
Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Oncology
OncLive - The Japanese Ministry of Health, Labour and Welfare has approved TAS-102 (trifluridine/tipiracil; Lonsurf) for the treatment of patients with unresectable advanced or recurrent gastric cancer that has progressed after chemotherapy.
Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Irinotecan Hydrochloride on Human Colorectal and Gastric Cancer Xenografts | Anticancer Research
Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Irinotecan Hydrochloride on Human Colorectal and Gastric Cancer Xenografts | Anticancer Research
TAGS: A Phase 3, Randomised, Double-blind Study of Trifluridine/Tipiracil ( TAS-102) Versus Placebo in Patients With Refractory Metastatic Gastric Cancer. - ppt download
Gastric Cancer Foundation lonsurf Archives | Gastric Cancer Foundation
Late-line treatment in metastatic gastric cancer: today and tomorrow | Semantic Scholar
Scenario 1. FLOT, TAS-102, IOs Do They Improve the Lives of Patients With Gastric Cancer? - ppt download
LONSURF® (trifluridine and tipiracil) tablets Efficacy | Previously Treated Metastatic GEJ and Gastric Cancer Treatment
